Literature DB >> 21720528

A patient with fragile x-associated tremor/ataxia syndrome presenting with executive cognitive deficits and cerebral white matter lesions.

Kensaku Kasuga1, Takeshi Ikeuchi, Keiko Arakawa, Ryuji Yajima, Takayoshi Tokutake, Masatoyo Nishizawa.   

Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder that primarily affects males who are carriers of a premutation of a CGG expansion in the FMR1 gene. In Asian populations, FXTAS has rarely been reported. Here, we report the case of a Japanese FXTAS patient who showed predominant executive cognitive deficits as the main feature of his disease. In contrast, the patient exhibited only very mild symptoms of intention tremor and ataxia, which did not interfere with daily activities. A gene analysis revealed that the patient carried a premutation of a CGG expansion (111 CGG repeats) in the FMR1 gene. The mRNA expression level of FMR1 in the patient was 1.5-fold higher than in controls. On brain MRI scans, fluid-attenuated inversion recovery images showed high-intensity lesions in the middle cerebellar peduncles and the cerebral white matter, with a frontal predominance. The present case extends previous notions regarding the cognitive impairment in FXTAS patients. Recognizing FXTAS patients with predominant cognitive impairment from various ethnic backgrounds would contribute to our understanding of the phenotypic variation of this disease.

Entities:  

Keywords:  CGG repeat expansion; Executive dysfunction; Fragile X-associated tremor/ataxia syndrome; Premutation; White matter lesion

Year:  2011        PMID: 21720528      PMCID: PMC3124446          DOI: 10.1159/000328838

Source DB:  PubMed          Journal:  Case Rep Neurol        ISSN: 1662-680X


Introduction

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder that primarily affects male carriers of a premutation expansion, ranging from 55 to 200 CGG repeats, in the FMR1 gene [1, 2]. The main features of FXTAS are intention tremor and gait ataxia. Less distinctive symptoms include parkinsonism, peripheral neuropathy, and cognitive decline [3]. Here, we report the case of a Japanese patient with a CGG premutation expansion in the FMR1 gene, who presented with predominant executive dysfunction and cerebral white matter lesions on MRI.

Case Report

A 59-year-old Japanese male patient first noticed occasional gait unsteadiness at the age of 44 years. The symptoms remained stable for a decade. There is no family history of mental retardation or neurological disease. His birth and early development were unremarkable. The patient gradually exhibited various cognitive symptoms including slowness in initiation and completion of simple tasks, excessive sleepiness during daytime, and poor concentration. He was referred to our hospital at the age of 59 years. On admission, detailed neuropsychological examinations were performed, the results of which are shown in table . General intellectual function, determined by the Wechsler Adult Intelligence Scale-III and Mini-Mental State Examination, was moderately impaired. The patient demonstrated poor performance in executive cognitive function tasks, examined by the Trail Making Test, Wisconsin Card Sorting Test, and Stroop test. His Frontal Assessment Battery score was also very low. Visual-spatial perception and language skills were preserved, and there were no signs of mood disorder or anxiety. On neurological examination, the patient showed mild intention tremor with terminal kinetic movement. His handwriting was well preserved. He showed mild truncal ataxia but was fully ambulant. There was no ataxia in his limbs, and muscle tendon reflexes in the extremities were attenuated. In addition, there was no sign of autonomic failure.
Table 1

Neuropsychological test results of the patient

TestResult
MMSE23/30
WAIS-III
 Verbal IQ81
 Performance IQ70
 Total IQ73
FAB5/18
Trail Making Test
 Part A210
 Part B744
Stroop test
 Word41
 Color65
 Interference24
WCST
 Category achieved0

MMSE = Mini-Mental State Examination; WAIS-III = Wechsler Adult Intelligence Scale, third edition; FAB = Frontal Assessment Battery; WCST = Wisconsin Card Sorting Test.

On brain MRI, fluid-attenuated inversion recovery images showed high-intensity lesions in the middle cerebellar peduncles (MCPs) (fig. ). Prominent cerebral white matter hyperintensities with a frontal predominance were also noted (fig. 1b, c). In addition, atrophy was observed in the cerebral cortex and cerebellar hemispheres. 99mTc-ethyl cysteinate dimer single-photon emission computed tomography revealed hypoperfusion in the cerebellum and the medial temporal lobe.
Fig. 1

MR images of the patient's brain. a An axial fluid-attenuated inversion recovery image shows high intensities in the bilateral MCPs, as indicated by arrowheads. In addition, atrophy in the pons, MCPs, and cerebellum can be identified. b, c Prominently increased signal intensities in the cerebral white matter as well as diffuse cortical atrophy can be observed.

On the basis of these findings, we suspected that the patient suffered from FXTAS, although he exhibited minor motor symptoms and predominant cognitive symptoms. We determined the CGG repeat in the FMR1 gene using genomic DNA extracted from peripheral blood leukocytes as previously reported [4]. PCR analysis showed that the patient carried a premutation of a CGG expansion (fig. ). The size of the premutation determined by a fluorescent-sequencer method was 111 CGG repeats (fig. 2b). We next examined the FMR1 mRNA expression level in peripheral blood. SYBR green real-time PCR assay was performed as previously reported [5]. In our patient, the mRNA expression level of the FMR1 gene, normalized to that of β-glucoronidase, was 1.5-fold higher than in 4 male healthy controls.
Fig. 2

Genetic molecular analysis of the FMR1 gene. a PCR-amplified genomic DNA samples from male control subjects (lanes 2-4) and the patient (lane 5) were run on a 2% agarose gel and stained with ethidium bromide. In the patient's sample (lane 5), the PCR product containing the premutation of CGG repeats is shown (arrow). The DNA size marker (M, lane 1) is a mixture of λ-HindIII and FX174-HaeIII digests. b The PCR product from the patient was further analyzed using an ABI3130x sequencer. The size of the premutation determined using GeneMapper software (version 4.0, Applied Biosystems) was 514 bp (arrowhead), which corresponds to approximately 111 CGG repeats.

Discussion

According to diagnostic criteria [2, 3], the present case is defined as definite FXTAS, because the patient showed 2 clinical features (intention tremor and gait ataxia) as well as 1 major radiological finding (MCPs). However, motor dysfunction due to ataxia and tremor was very mild and did not interfere with activities of daily life. In contrast, the patient showed prominent executive cognitive deficits as the predominant feature of his disease. In recent years, cognitive impairments in FXTAS patients have increasingly been investigated [6, 7, 8]. The cognitive phenotype of FXTAS is characterized by fronto-subcortical dementia with impairment of executive functioning [9, 10]. It is as yet unknown when cognitive impairment begins in relation to the neurological signs of FXTAS. Gonçalves et al. [11] reported the case of a 70-year-old patient with atypical FXTAS, who presented rapidly progressive dementia as the major symptom. We here showed that our Japanese FXTAS patient exhibited frontal and executive dysfunctions characterized by psychomotor slowness, bradyphrenia, distractibility as well as attention and concentration difficulties. Prominent hyperintensities in the cerebral white matter with a frontal dominance might be attributable to the development of these manifestations in the patient. These findings extend the previous notions regarding the cognitive impairment associated with FXTAS. Asian patients with FXTAS have rarely been reported in the literature. The exact reason for this is currently unknown. Recently, Ishii et al. [12] reported the first Japanese FXTAS patient who was initially diagnosed with essential tremor. Recognizing FXTAS patients with predominant cognitive impairment would contribute to our understanding of the disease's phenotypic variation. Genetic testing should be considered in patients with unidentified causes of cognitive impairment, particularly when an MRI shows hyperintensities in the cerebral white matter and/or MCPs.

Disclosure Statement

The authors have no conflicts of interest to declare.
  12 in total

1.  Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X.

Authors:  R J Hagerman; M Leehey; W Heinrichs; F Tassone; R Wilson; J Hills; J Grigsby; B Gage; P J Hagerman
Journal:  Neurology       Date:  2001-07-10       Impact factor: 9.910

2.  Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.

Authors:  F Tassone; R J Hagerman; A K Taylor; L W Gane; T E Godfrey; P J Hagerman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

3.  Atypical clinical course of FXTAS: rapidly progressive dementia as the major symptom.

Authors:  M R R Gonçalves; L P Capelli; R Nitrini; E R Barbosa; C S Porto; L T Lucato; A M Vianna-Morgante
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

4.  An enhanced polymerase chain reaction assay to detect pre- and full mutation alleles of the fragile X mental retardation 1 gene.

Authors:  Alessandro Saluto; Alessandro Brussino; Flora Tassone; Carlo Arduino; Claudia Cagnoli; Patrizia Pappi; Paul Hagerman; Nicola Migone; Alfredo Brusco
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

5.  Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS).

Authors:  Jim Grigsby; Angela G Brega; Sébastien Jacquemont; Danuta Z Loesch; Maureen A Leehey; Glenn K Goodrich; Randi J Hagerman; Jennifer Epstein; Rebecca Wilson; Jennifer B Cogswell; Tristan Jardini; Flora Tassone; Paul J Hagerman
Journal:  J Neurol Sci       Date:  2006-06-15       Impact factor: 3.181

6.  Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome.

Authors:  Jim Grigsby; Angela G Brega; Maureen A Leehey; Glenn K Goodrich; Sébastien Jacquemont; Danuta Z Loesch; Jennifer B Cogswell; Jennifer Epstein; Rebecca Wilson; Tristan Jardini; Emma Gould; Rachael E Bennett; David Hessl; Susannah Cohen; Kylee Cook; Flora Tassone; Paul J Hagerman; Randi J Hagerman
Journal:  Mov Disord       Date:  2007-04-15       Impact factor: 10.338

7.  A Japanese case of fragile-X-associated tremor/ataxia syndrome (FXTAS).

Authors:  Kazuhiro Ishii; Ai Hosaka; Kaori Adachi; Eiji Nanba; Akira Tamaoka
Journal:  Intern Med       Date:  2010-06-15       Impact factor: 1.271

8.  Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome.

Authors:  James A Bourgeois; Jennifer B Cogswell; David Hessl; Lin Zhang; Michele Y Ono; Flora Tassone; Faraz Farzin; James A Brunberg; Jim Grigsby; Randi J Hagerman
Journal:  Gen Hosp Psychiatry       Date:  2007 Jul-Aug       Impact factor: 3.238

Review 9.  Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines.

Authors:  Elizabeth Berry-Kravis; Liane Abrams; Sarah M Coffey; Deborah A Hall; Claudia Greco; Louise W Gane; Jim Grigsby; James A Bourgeois; Brenda Finucane; Sebastien Jacquemont; James A Brunberg; Lin Zhang; Janet Lin; Flora Tassone; Paul J Hagerman; Randi J Hagerman; Maureen A Leehey
Journal:  Mov Disord       Date:  2007-10-31       Impact factor: 10.338

10.  Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates.

Authors:  Sébastien Jacquemont; Randi J Hagerman; Maureen Leehey; Jim Grigsby; Lin Zhang; James A Brunberg; Claudia Greco; Vincent Des Portes; Tristan Jardini; Richard Levine; Elizabeth Berry-Kravis; W Ted Brown; Stephane Schaeffer; John Kissel; Flora Tassone; Paul J Hagerman
Journal:  Am J Hum Genet       Date:  2003-03-12       Impact factor: 11.025

View more
  4 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

2.  Clinicopathological features of adult-onset neuronal intranuclear inclusion disease.

Authors:  Jun Sone; Keiko Mori; Tomonori Inagaki; Ryu Katsumata; Shinnosuke Takagi; Satoshi Yokoi; Kunihiko Araki; Toshiyasu Kato; Tomohiko Nakamura; Haruki Koike; Hiroshi Takashima; Akihiro Hashiguchi; Yutaka Kohno; Takashi Kurashige; Masaru Kuriyama; Yoshihisa Takiyama; Mai Tsuchiya; Naoyuki Kitagawa; Michi Kawamoto; Hajime Yoshimura; Yutaka Suto; Hiroyuki Nakayasu; Naoko Uehara; Hiroshi Sugiyama; Makoto Takahashi; Norito Kokubun; Takuya Konno; Masahisa Katsuno; Fumiaki Tanaka; Yasushi Iwasaki; Mari Yoshida; Gen Sobue
Journal:  Brain       Date:  2016-10-25       Impact factor: 13.501

Review 3.  Cognitive Dysfunction in Repeat Expansion Diseases: A Review.

Authors:  Sizhe Zhang; Lu Shen; Bin Jiao
Journal:  Front Aging Neurosci       Date:  2022-04-11       Impact factor: 5.750

4.  Prevalence of Fragile X-Associated Tremor/Ataxia Syndrome in Patients with Cerebellar Ataxia in Japan.

Authors:  Yujiro Higuchi; Masahiro Ando; Akiko Yoshimura; Satoshi Hakotani; Yuki Koba; Yusuke Sakiyama; Yu Hiramatsu; Yuichi Tashiro; Yoshimitsu Maki; Akihiro Hashiguchi; Junhui Yuan; Yuji Okamoto; Eiji Matsuura; Hiroshi Takashima
Journal:  Cerebellum       Date:  2021-09-09       Impact factor: 3.648

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.